Big firms to discuss introduction of biosimilar substitution in France
This article was originally published in Scrip
Executive Summary
Some of the big guns of the biopharmaceutical and generics industries are to take part in a working group set up to determine just how biosimilar substitution is to be implemented in France, following the publication of the 2014 social security financing law (LFSS) allowing pharmacists to substitute a biosimilar for a prescribed biological in certain circumstances.